David James Lennon Sells 26,858 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) CEO David James Lennon sold 26,858 shares of Whitehawk Therapeutics stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $3.48, for a total value of $93,465.84. Following the sale, the chief executive officer directly owned 793,549 shares in the company, valued at approximately $2,761,550.52. The trade was a 3.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

David James Lennon also recently made the following trade(s):

• On Monday, March 2nd, David James Lennon sold 5,100 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.31, for a total value of $16,881.00.

Whitehawk Therapeutics Stock Performance

Shares of NASDAQ:WHWK opened at $3.51 on Friday. The firm has a market capitalization of $165.67 million, a P/E ratio of 7.47 and a beta of 0.57. The stock has a 50 day moving average price of $3.28 and a 200-day moving average price of $2.66. Whitehawk Therapeutics, Inc. has a 52-week low of $1.39 and a 52-week high of $4.48.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.21.

Hedge Funds Weigh In On Whitehawk Therapeutics

Several large investors have recently modified their holdings of the stock. Avoro Capital Advisors LLC purchased a new stake in Whitehawk Therapeutics during the 3rd quarter valued at about $5,414,000. Suvretta Capital Management LLC purchased a new position in Whitehawk Therapeutics in the third quarter worth about $7,030,000. Ally Bridge Group NY LLC purchased a new position in Whitehawk Therapeutics in the third quarter worth about $1,554,000. Peapod Lane Capital LLC bought a new position in shares of Whitehawk Therapeutics in the third quarter worth approximately $577,000. Finally, Orbimed Advisors LLC bought a new position in shares of Whitehawk Therapeutics in the third quarter worth approximately $7,915,000. Hedge funds and other institutional investors own 52.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on WHWK. JonesTrading began coverage on shares of Whitehawk Therapeutics in a research report on Monday, December 22nd. They issued a “buy” rating and a $7.00 target price on the stock. Oppenheimer initiated coverage on shares of Whitehawk Therapeutics in a research report on Thursday, February 5th. They set an “outperform” rating and a $6.00 price target for the company. Wall Street Zen raised shares of Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Whitehawk Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $6.50.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.